23 results on '"Angioni, D"'
Search Results
2. Clinical Meaningfulness in Alzheimer’s Disease Clinical Trials. A Report from the EU-US CTAD Task Force
- Author
-
Angioni, D., Cummings, J., Lansdall, C. J., Middleton, L., Sampaio, C., Gauthier, S., Cohen, S., Petersen, R. C., Rentz, D. M., Wessels, A. M., Hendrix, S. B., Jessen, F., Carrillo, M. C., Doody, R. S., Irizarry, M., Andrews, J. S., Vellas, B., Aisen, P., Andrieu, Sandrine, Bateman, Randall, Batrla, Richard, Bell, Joanne, Bosson, Oskar, Bozeat, Sasha, Brooks, Dawn, Haeberlein, Samantha Budd, Buracchio, Teresa, Cho, Min, Choung, Matthew, Cook, Gavin, Crisitello, Darrin, Dangond, Fernando, de Santi, Susan, Dennehy, Ellen, Dhadda, Shobha, Dhillon, Harjeet, Dunn, Billy, Egan, Michael, Elwood, Fiona, Eriksson, Sven, Fagan, Tom, Fillit, Howard, Freskgard, Per-Ola, Gallagher, Diana, Gangi, Gopi, Granda, Carlos, Greeley, David, Gronblad, Anna-Kaija, Hampel, Harald, Hawthorne, Paul, Henley, David, Herring, Joe, Hersch, Steve, Holt, Bill, Iwatsubo, Takeshi, Jones, Daryl, Kahl, Anja, Kinney, Gene, Kolb, Hartmuth, Kramer, Lynn, Kulic, Luka, Kumar, Sanjay, Lannfelt, Lars, Lawson, John, Legrand, Valérie, Lenington, Rachel, Longo, Frank, Matthews, Brandy, Masterman, Donna, McLinden, Kristina, Mikels, Sarah, Miller, Michael, Mintun, Mark, Moebius, Hans, Monteiro, Cecilia, Morken, Mario, Murphy, Jennifer, Odergren, Tomas, Osswald, Gunilla, Parnas, Laura, Patru, Maria-Magdalena, Prazma, Charlene, Raman, Rema, Reyderman, Larisa, Rogers, Sharon, Roman, Lise, Romano, Gary, Roskey, Mark, Rubino, Ivana, Ryan, Laurie, Salloway, Stephen, Schindler, Rachel, Schneider, Lon, Scott, David, Sims, John, Skovronsky, Daniel, Soto, Marion, Sperling, Reisa, Steukers, Lennert, Stoops, Erik, Strittmatter, Stephen, Tahami, Amir, Tamagnan, Gilles, Tariot, Gilles, Toloue, Masoud, Touchon, Jacques, Vanmechelen, Eugeen, Walt, Len, Weinberg, Mark, Weiner, Michael, White, Anne, Wiesel, Iris, Wilson, David, Yarenis, Lisa, Zago, Wagner, and Zhou, Jin
- Published
- 2024
- Full Text
- View/download PDF
3. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
- Author
-
Angioni, D., Hansson, O., Bateman, R. J., Rabe, C., Toloue, M., Braunstein, J. B., Agus, S., Sims, J. R., Bittner, T., Carrillo, M. C., Fillit, H., Masters, C. L., Salloway, S., Aisen, P., Weiner, M., Vellas, B., Gauthier, S., Abushakra, Susan, Afshar, Mohammad, Alam, John, Algeciras-Schimnich, Alicia, Andrieu, Sandrine, Ballard, Clive, Baruch, Amos, Batrla, Richard, Baudler, Monika, Bell, Joanne, Bozeat, Sasha, Brooks, Dawn, Brooks, Tricia, Bullain, Szofia, Burmeister, Jan, Cho, Min, Collins, Emily, Cook, Gavin, Cummings, Jeffrey, Dague, Chris, De Santi, Susan, Doody, Rachelle, Dunn, Billy, Egan, Michael, Eriksson, Sven, Esquivel, Rianne, Fagan, Tom, Ferrell, Phyllis, Gallagher, Michela, Grönblad, Anna-Kaija, Hains, Avis, Hampel, Harald, Hefting, Nanco, Hendrix, Suzanne, Ho, Carole, Hu, Helen, Ismail, Zahinoor, Jones, Daryl, Kinney, Gene, Kinnon, Paul, Kurzman, Ricky, Lannfelt, Lars, Lawson, John, LeBastard, Nathalie, Legrand, Valérie, Lewandowski, Nicole, Lim, Carine, Lyketsos, Costantine, Masterman, Donna, Lu, Ming, Mintun, Mark, Molinuevo, José Luis, Monteiro, Cecilia, Navia, Bradford, Odergren, Tomas, Osswald, Gunilla, Penny, Lewis, Pontecorvo, Michael, Porsteinsson, Anton, Raman, Rema, Respondek, Gesine, Reyderman, Larisa, Rogers, Sharon, Rosenberg, Paul, Rosenzweig-Lipson, Sharon, Roskey, Mark, Carrie, Rubel, Saad, Ziad, Schindler, Rachel, Selkoe, Dennis, Shulman, Melanie, Sink, Kaycee, Sipe, Lisa, Skovronsky, Daniel, Somers, Elizabeth, Soto, Maria, Streffer, Johannes, Such, Pedro, Suhy, Joyce, Touchon, Jacques, Vandijck, Manu, White, Anne, Wilson, David, Zago, Wagner, and Zhou, Jin
- Published
- 2023
- Full Text
- View/download PDF
4. Sarcopenia and poor nutritional status in older adults
- Author
-
Calcaterra, L., Abellan van Kan, G., Steinmeyer, Z., Angioni, D., Proietti, M., and Sourdet, S.
- Published
- 2024
- Full Text
- View/download PDF
5. Resilience: Biological Basis and Clinical Significance — A Perspective Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force
- Author
-
Cesari, Matteo, Azzolino, D., LeBrasseur, N. K., Whitson, H., Rooks, D., Sourdet, S., Angioni, D., Fielding, R. A., Vellas, B., Rolland, Y., Andrieu, Sandrine, Leheudre, Mylène Aubertin, Barcons, Nuria, Beliën, Ann, de Souto Barreto, Philipe, Delannoy, Carla, John, Groarke, Robledo, Luis Miguel Gutierrez, Hwee, Darren, Mariani, Jean, Reshma, Merchant, Morley, John, Pereira, Suzette, Erin, Quann, Michelle, Rossulek, Rueda, Ricardo, Tarasenko, Lisa, Tourette, Cendrine, Van Maanen, Rob, and Waters, Debra L.
- Published
- 2022
- Full Text
- View/download PDF
6. Biomarkers of Age-Related Frailty and Frailty Related to Diseases: An Exploratory, Cross-Sectional Analysis from the MAPT Study
- Author
-
Angioni, D., Lu, W. H., Sourdet, S., Macaron, T., Takeda, C., Guyonnet, S., Mangin, J. F., Rolland, Y., de Souto Barreto, P., and Vellas, B.
- Published
- 2022
- Full Text
- View/download PDF
7. Framework Implementation of the INSPIRE ICOPE-CARE Program in Collaboration with the World Health Organization (WHO) in the Occitania Region
- Author
-
Tavassoli, Neda, Piau, A., Berbon, C., de Kerimel, J., Lafont, C., De Souto Barreto, P., Guyonnet, S., Takeda, C., Carrie, I., Angioni, D., Paris, F., Mathieu, C., Ousset, P. J., Balardy, L., Voisin, T., Sourdet, S., Delrieu, J., Bezombes, V., Pons-Pretre, V., Andrieu, S., Nourhashemi, F., Rolland, Y., Soto, M. E., Beard, J., Sumi, Y., Araujo Carvalho, I., and Vellas, B.
- Published
- 2021
- Full Text
- View/download PDF
8. Age-Related Frailty: A Clinical Model for Geroscience?
- Author
-
Takeda, Catherine, Angioni, D., Setphan, E., Macaron, T., De Souto Barreto, P., Sourdet, S., Sierra, F., and Vellas, B.
- Published
- 2020
- Full Text
- View/download PDF
9. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
- Author
-
Angioni, D, Angioni, D, Delrieu, J, Hansson, O, Fillit, H, Aisen, P, Cummings, J, Sims, JR, Braunstein, JB, Sabbagh, M, Bittner, T, Pontecorvo, M, Bozeat, S, Dage, JL, Largent, E, Mattke, S, Correa, O, Gutierrez Robledo, LM, Baldivieso, V, Willis, DR, Atri, A, Bateman, RJ, Ousset, P-J, Vellas, B, Weiner, M, Angioni, D, Angioni, D, Delrieu, J, Hansson, O, Fillit, H, Aisen, P, Cummings, J, Sims, JR, Braunstein, JB, Sabbagh, M, Bittner, T, Pontecorvo, M, Bozeat, S, Dage, JL, Largent, E, Mattke, S, Correa, O, Gutierrez Robledo, LM, Baldivieso, V, Willis, DR, Atri, A, Bateman, RJ, Ousset, P-J, Vellas, B, and Weiner, M
- Abstract
Timely and accurate diagnosis of Alzheimer's disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.
- Published
- 2022
10. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
- Author
-
Angioni, D., primary, Delrieu, J., additional, Hansson, O., additional, Fillit, H., additional, Aisen, P., additional, Cummings, J., additional, Sims, J.R., additional, Braunstein, J.B., additional, Sabbagh, M., additional, Bittner, T., additional, Pontecorvo, M., additional, Bozeat, S., additional, Dage, J.L., additional, Largent, E., additional, Mattke, S., additional, Correa, O., additional, Gutierrez Robledo, L.M., additional, Baldivieso, V., additional, Willis, D.R., additional, Atri, A., additional, Bateman, R.J., additional, Ousset, P-J., additional, Vellas, B., additional, and Weiner, M., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Framework Implementation of the INSPIRE ICOPE-CARE program in collaboration with the World Health Organization (WHO) in the Occitania region
- Author
-
Tavassoli, N., primary, Piau, A., additional, Berbon, C., additional, De Kerimel, J., additional, Lafont, C., additional, De Souto Barreto, P., additional, Guyonnet, S., additional, Takeda, C., additional, Carrie, I., additional, Angioni, D., additional, Paris, F., additional, Mathieu, C., additional, Ousset, P.J., additional, Balardy, L., additional, Voisin, T., additional, Sourdet, S., additional, Delrieu, J., additional, Bezombes, V., additional, Pons-Pretre, V., additional, Andrieu, S., additional, Nourhashemi, F., additional, Rolland, Y., additional, Soto, M.E., additional, Beard, J., additional, Sumi, Y., additional, Araujo Carvalho, I., additional, and Vellas, B., additional
- Published
- 2020
- Full Text
- View/download PDF
12. PREDICTIVE FACTORS OF IN-HOSPITAL MORTALITY IN OLDER ADULTS WITH COMMUNITY-ACQUIRED BLOODSTREAM INFECTION
- Author
-
Angioni, D., primary, Hites, M., additional, Jacobs, F., additional, and De Breucker, S., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Increased trend in dementia incidence within a Taiwanese National Cohort: What have we learned? What can we do?
- Author
-
Angioni D, Ousset PJ, and Vellas B
- Subjects
- Humans, Incidence, Cohort Studies, Learning, Taiwan epidemiology, Dementia epidemiology
- Abstract
Competing Interests: Declaration of competing interest None.
- Published
- 2024
- Full Text
- View/download PDF
14. Drugs for Alzheimer's disease: Where are we coming from? Where are we going?
- Author
-
Angioni D, Delrieu J, Coley N, Ousset PJ, Shi J, and Vellas B
- Subjects
- Humans, Amyloid beta-Peptides metabolism, Alzheimer Disease drug therapy
- Published
- 2024
- Full Text
- View/download PDF
15. Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review.
- Author
-
Angioni D, Raffin J, Ousset PJ, Delrieu J, and de Souto Barreto P
- Subjects
- Humans, Cross-Sectional Studies, Donepezil therapeutic use, Brain, Amyloid beta-Peptides metabolism, Randomized Controlled Trials as Topic, Alzheimer Disease complications, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Cognition Disorders
- Abstract
Background: Fatigue is a common symptom in neurodegenerative diseases and is associated with decreased cognitive performances. A full knowledge of the causes and physiopathological pathways leading to fatigue in Alzheimer's disease could help treating this symptom and obtain positive effects on cognitive functions., Objectives: To provide an overview of the clinical conditions and the biological mechanisms leading to fatigue in Alzheimer's disease patients. To review the recent advances on fatigue management and describe the landscape of future possibilities., Methods: We performed a narrative review including all type of studies (e.g. cross-sectional and longitudinal analysis, reviews, clinical trials)., Results: We found very few studies considering the symptom fatigue in Alzheimer's disease patients. Populations, designs, and objectives varied across studies rendering comparability across studies difficult to perform. Results from cross-sectional and longitudinal analysis suggest that the amyloid cascade may be involved in the pathogenesis of fatigue and that fatigue may be a prodromal manifestation of Alzheimer's disease. Fatigue and neurodegeneration of Alzheimer's disease could share common brain signatures (i.e. hippocampal atrophy and periventricular leukoaraiosis). Some mechanisms of aging (i.e. inflammation, mitochondrial dysfunction, telomere shortening) may be proposed to play a common underlying role in Alzheimer's disease neurodegeneration and muscle fatigability. Considering treatments, donepezil has been found to reduce cognitive fatigue in a 6-week randomized controlled study. Fatigue is frequently reported as an adverse event in patients treated by anti-amyloid agents in clinical trials., Conclusion: The literature is actually inconclusive about the main causes of fatigue in Alzheimer's disease individuals and its potential treatments. Further research is needed to disentangle the role of several components such as comorbidities, depressive symptoms, iatrogenic factors, physical decline and neurodegeneration itself. Given the clinical relevance of this symptom, it seems to be important to systematically assess fatigue by validated tools in Alzheimer's disease clinical trials., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
16. Challenges in developing Geroscience trials.
- Author
-
Rolland Y, Sierra F, Ferrucci L, Barzilai N, De Cabo R, Mannick J, Oliva A, Evans W, Angioni D, De Souto Barreto P, Raffin J, Vellas B, and Kirkland JL
- Subjects
- Humans, Aging, Research Personnel, Geroscience, Advisory Committees
- Abstract
Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
17. Neuroimaging correlates of persistent fatigue in older adults: A secondary analysis from the Multidomain Alzheimer Preventive Trial (MAPT) trial.
- Author
-
Angioni D, Cesari M, Raffin J, Virecoulon Giudici K, Mangin JF, Bouyahia A, Chupin M, Fischer C, Gourieux E, Rolland Y, De Breucker S, Vellas B, and de Souto Barreto P
- Subjects
- Aged, Brain diagnostic imaging, Cross-Sectional Studies, Fatigue diagnostic imaging, Female, Humans, Magnetic Resonance Imaging methods, Male, Neuroimaging, tau Proteins, Alzheimer Disease diagnostic imaging
- Abstract
Objectives: Fatigue has been suggested as a marker of biological aging. It seems plausible that this symptom might be associated with changes in brain health. The objective of this study was to examine the associations between persistent fatigue and neuroimaging correlates in a non-disease-specific population of community-dwelling older adults., Methods: We performed a cross-sectional analysis using data from The Multidomain Alzheimer Preventive Trial (MAPT). We included 458 subjects. Persistent fatigue was defined as meeting exhaustion criterion of Fried frailty phenotype in two consecutive clinical visits six months apart between study baseline and one year. Brain imaging correlates, assessed by magnetic resonance imaging (MRI), were the outcomes. The associations between persistent fatigue and brain correlates were explored using mixed model linear regressions with random effect at the center level., Results: The mean age of the participants was 74.8 ± 4 years old, and 63% of the subjects were women. Forty-seven participants (10%) exhibited a persistent fatigue profile. People with persistent fatigue were older compared to subjects without persistent fatigue (76.2 years ± 4.3 vs.74.7 ± 3.9 p = 0.009). Persistent fatigue was associated with higher white matter hyperintensity volume in the fully adjusted analysis. We did not find any cross-sectional association between persistent fatigue and sub-cortical volumes and global and regional cortical thickness., Conclusion: Persistent fatigue was cross-sectionnally associated with higher white matter hyperintensity volume in older adults. Further longitudinal studies, using an assessment tool specifically designed and validated for measuring fatigue, are needed to confirm our findings.
- Published
- 2022
- Full Text
- View/download PDF
18. Physical Activity, Body Mass Index, and Blood Progranulin in Older Adults: Cross-Sectional Associations in the MAPT Study.
- Author
-
Raffin J, Angioni D, Giudici KV, Valet P, Aggarwal G, Nguyen AD, Morley JE, Guyonnet S, Rolland Y, Vellas B, and de Souto Barreto P
- Subjects
- Aged, Aged, 80 and over, Body Mass Index, Cross-Sectional Studies, Exercise, Humans, Obesity, Progranulins, Alzheimer Disease
- Abstract
Physical activity (PA) has been shown to moderate the negative effects of obesity on pro-inflammatory cytokines but its relationship with the adipokine progranulin (PGRN) remains poorly investigated. This study aimed to examine the cross-sectional main and interactive associations of body mass index (BMI) and PA level with circulating PGRN in older adults. Five-hundred and twelve participants aged 70 years and older involved in the Multidomain Alzheimer Preventive Trial (MAPT) study who underwent plasma PGRN measurements (ng/mL) were included. Self-reported PA levels were assessed using questionnaires. People were classified into 3 BMI categories: normal weight, overweight, or obesity. Further categorization using PA tertiles was used to define highly active, moderately active, and low active individuals. Multiple linear regressions were performed in order to test the associations of BMI, PA level, and their interaction with PGRN levels. Multiple linear regressions adjusted by age, sex, diabetes mellitus status, total cholesterol, creatinine level, and MAPT group demonstrated significant interactive associations of BMI status and continuous PA such that in people without obesity, higher PA levels were associated with lower PGRN concentrations, while an opposite pattern was found in individuals with obesity. In addition, continuous BMI was positively associated with circulating PGRN in highly active individuals but not in their less active peers. This cross-sectional study demonstrated reverse patterns in older adults with obesity compared to those without obesity regarding the relationships between PA and PGRN levels. Longitudinal and experimental investigations are required to understand the mechanisms that underlie the present findings. Clinical Trials Registration Number: NCT00672685., (© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
19. Neuroimaging markers of chronic fatigue in older people: a narrative review.
- Author
-
Angioni D, Virecoulon Giudici K, Montoya Martinez M, Rolland Y, Vellas B, and de Souto Barreto P
- Subjects
- Aged, Basal Ganglia, Humans, Magnetic Resonance Imaging, Neuroimaging, Fatigue Syndrome, Chronic, White Matter
- Abstract
Background: Chronic fatigue is a common symptom in older adults. Although some studies have attempted to identify the neuronal correlates of fatigue associated with chronic diseases, the scientific evidence is scarce regarding fatigue in older people not suffering from a specific disease., Aims: To gather available evidence of neuroimaging studies investigating the associations between fatigue and brain health in older adults out of the context of a specific disease, and to identify potential brain structures associated with this symptom., Methods: Studies considering exclusively patients with a specific disease and/or studies focusing on physiological mechanisms of acute fatigue induced by the realization of cognitive and physical tasks were excluded., Results: Very few studies on the associations of fatigue with neuroimaging markers are currently available. Fatigue was associated with reduced hippocampus volumes and with hippocampal amyloid deposition. Regarding the association between fatigue and the circuit of basal ganglia, putamen and thalamus were associated with physical fatigability, whereas amygdala and thalamus with mental fatigability. Very limited evidence about white matter integrity found that healthy individuals with high levels of fatigue had a greater total volume of leukoaraiosis., Conclusion: This review suggests that hippocampus damage and potentially loss of function in basal ganglia networks could play a role on chronic fatigue during aging. Further studies are needed to assess the associations of fatigue with white matter alterations.
- Published
- 2021
- Full Text
- View/download PDF
20. Intrinsic Capacity Assessment by a Mobile Geriatric Team During the Covid-19 Pandemic.
- Author
-
Angioni D, Nicolay C, Vandergheynst F, Baré R, Cesari M, and De Breucker S
- Abstract
In the autumn of 2020, the second wave of the COVID-19 pandemic hit Europe. In this context, because of the insufficient number of beds in geriatric COVID units, non-geriatric wards were confronted with a significant number of admissions of geriatric patients. In this perspective article, we describe the role of a mobile geriatric team in the framework of the COVID-19 pandemic and specifically how it assisted other specialists in the management of hospitalized geriatric patients by implementing a new approach: the systematic assessment and optimization of Intrinsic Capacity functions. For each patient, assessed by this consultative team, an individualized care plan, including an anticipated end-of-life decision-making process, was established. Intensity of care was most often not stated by considering chronological age but rather the comorbidity burden, the frailty status, and the patient's wishes. Further studies are needed to determine if this mobile geriatric team approach was beneficial in terms of mortality, length of stay, or functional, psychological, and cognitive outcomes in COVID-19 geriatric patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Angioni, Nicolay, Vandergheynst, Baré, Cesari and De Breucker.)
- Published
- 2021
- Full Text
- View/download PDF
21. [The digital tool for the prevention of dependency in the elderly].
- Author
-
Macaron T, Angioni D, Vellas B, and Oliveira Soares C
- Subjects
- Aged, Humans, Aging, Life Expectancy
- Abstract
Dependency care is a real public health issue. The lengthening of life expectancy and the increase in polypathologies require health policies that are as close as possible to the needs of the elderly. The World Health Organisation has set up a program to encourage healthy ageing. Based on this program, the Toulouse gerontopôle has developed digital tools for the prevention, evaluation, monitoring and management of ageing in order to detect and monitor 200,000 elderly people in Occitania within five years., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Can We Distinguish Age-Related Frailty from Frailty Related to Diseases ? Data from the MAPT Study.
- Author
-
Angioni D, Macaron T, Takeda C, Sourdet S, Cesari M, Virecoulon Giudici K, Raffin J, Lu WH, Delrieu J, Touchon J, Rolland Y, de Souto Barreto P, and Vellas B
- Subjects
- Aged, Aged, 80 and over, Comorbidity, Female, Humans, Male, Frail Elderly psychology, Frailty epidemiology, Geriatric Assessment methods
- Abstract
Background: No study has tried to distinguish subjects that become frail due to diseases (frailty related to diseases) or in the absence of specific medical events; in this latter case, it is possible that aging process would act as the main frailty driver (age-related frailty)., Objectives: To classify subjects according to the origin of physical frailty: age-related frailty, frailty related to diseases, frailty of uncertain origin, and to compare their clinical characteristics., Materials and Methods: We performed a secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT), including 195 subjects ≥70 years non-frail at baseline who became frail during a 5-year follow-up (mean age 77.8 years ± 4.7; 70% female). Physical frailty was defined as presenting ≥3 of the 5 Fried criteria: weight loss, exhaustion, weakness, slowness, low physical activity. Clinical files were independently reviewed by two different clinicians using a standardized assessment method in order to classify subjects as: "age-related frailty", "frailty related to diseases" or "frailty of uncertain origin". Inconsistencies among the two raters and cases of uncertain frailty were further assessed by two other experienced clinicians., Results: From the 195 included subjects, 82 (42%) were classified as age-related frailty, 53 (27%) as frailty related to diseases, and 60 (31%) as frailty of uncertain origin. Patients who became frail due to diseases did not differ from the others groups in terms of functional, cognitive, psychological status and age at baseline, however they presented a higher burden of comorbidity as measured by the Cumulative Illness Rating Scale (CIRS) (8.20 ± 2.69; vs 6.22 ± 2.02 frailty of uncertain origin; vs. 3.25 ± 1.65 age-related frailty). Time to incident frailty (23.4 months ± 12.1 vs. 39.2 ± 19.3 months) and time spent in a pre-frailty condition (17.1 ± 11.4 vs 26.6 ± 16.6 months) were shorter in the group of frailty related to diseases compared to age-related frailty. Orthopedic diseases (n=14, 26%) were the most common pathologies leading to frailty related to diseases, followed by cardiovascular diseases (n=9, 17%) and neurological diseases (n = 8, 15%)., Conclusion: People classified as age-related frailty and frailty related to diseases presented different frailty-associated indicators. Future research should target the underlying biological cascades leading to these two frailty classifications, since they could ask for distinct strategies of prevention and management., Competing Interests: M.C. served as a consultant for and/or received honoraria for scientific presentations from Nestlé.
- Published
- 2020
- Full Text
- View/download PDF
23. Predictive Factors of In-Hospital Mortality in Older Adults with Community-Acquired Bloodstream Infection.
- Author
-
Angioni D, Hites M, Jacobs F, and De Breucker S
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Retrospective Studies, Risk Factors, Bacteremia mortality, Community-Acquired Infections mortality, Hospital Mortality trends
- Abstract
Objectives: To assess the prevalence of intra-hospital mortality and associated risk factors in older people aged 75+, admitted with blood stream infections (BSI)., Design: Single center retrospective study performed in an 850-bed of the academic hospital of the Université Libre de Bruxelles., Setting and Participants: From January 2015 to December 2017, all inpatients over 75 years old admitted with BSI were included., Measures: Demographical, clinical and microbiological data were collected., Results: 212 patients were included: median age was 82 [79-85] years and 60 % were female. The in-hospital mortality rate was 19%. The majority of microorganisms were Gram-negative strains, of which Escherichia coli was the most common, and urinary tract infection was the most common origin of BSI. Compared to patients who survived, the non-survivor group had a higher SOFA score (6 versus 3, p<0.0001), a higher comorbidity score (5 versus 4, p<0.0001), more respiratory tract infections (28 vs 6 %, p < 0.0001) and fungal infections (5 vs 1 %, p = 0.033), bedridden status (60 vs 25 %, p < 0.0001), and healthcare related infections (60 vs 40 %, p = 0.019). Using Cox multivariable regression analysis, only SOFA score was independently associated with mortality (HR 1.75 [95%IC 1.52-2.03], p<0.0001)., Conclusions and Implications: BSI in older people are severe infections associated with a significant in-hospital mortality. Severity of clinical presentation at onset remains the most important predictor of mortality for BSI in older people. BSI originating from respiratory source and bedridden patients are at greater risk of intra-hospital mortality. Further prospective studies are needed to confirm these results., Competing Interests: The author(s) declare(s) that there is no conflict of interest regarding the publication of this article.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.